MASSDEVICE ON CALL — Medical device giant Edwards Lifesciences (NYSE:EW) has a rosy outlook for the future, including an anticipated doubling of its Utah workforce from about 500 to 1,000 employees.
Edwards Lifesciences
Early TAVI devices still looking good at 5 years | MassDevice.com On Call
MASSDEVICE ON CALL — Results from the one of the 1st in-human studies of transcatheter aortic valve implants proved that the devices remained durable and effective 5 years after treatment, researchers found.
Edwards Lifesciences gains on affirmed earnings guidance, 2013 forecast | Wall Street Beat
Edwards Lifesciences (NYSE:EW) reinforced its guidance for the rest of 2012 and issued its forecast for next year ahead of its annual investor conference today at its headquarters in Irvine, Calif.
Edwards wins Chinese approval for Perimount mitral valve
Medical device giant Edwards Lifesciences (NYSE:EW) touted China State Food & Drug Administration approval for its Carpentier-Edwards Perimount replacement mitral heart valve, part of the Perimount suite of devices that Edwards says are "the world’s most frequently implanted valves for more than 30 years."
Heart valves: St. Jude Medical reports 1st transapical TAVI patient
St. Jude Medical (NYSE:STJ) reported a milestone for its Portico heart valve today, saying the 1st patient was given the transcatheter aortic valve implant via a catheter threaded through an incision in the apex of the heart’s left ventricle.
Medtronic brass: Edwards lawsuit hits profits, but has no impact on CoreValve timeline
Survey: Heart docs say Edwards on track for solid heart valve growth | Wall Street Beat
Edwards Lifesciences (NYSE:EW) is on track for solid growth in the transcatheter aortic valve implant market, according to a survey of cardiologists conducted by Leerink Swann analysts.
Appeals court upholds $74M Edwards Lifesciences win over Medtronic
UPDATED Nov. 13, 2012, 5:30 p.m. with comment from Medtronic
UPDATED Nov. 13, 2012, 2:30 p.m. with comment from Edwards Lifesciences
Edwards Lifesciences: Feds closed probe into recalled Vigilance I heart monitor
Edwards Lifesciences (NYSE:EW) said a federal probe into its Vigilance I heart monitor, which it recalled in 2006, has been called off.
TAVI: Mixed results for Edwards’ Sapien valve in latest Partner analysis
Newly unveiled results from Edwards Lifesciences (NYSE:EW) transcatheter aortic valve studies showed mixed results for its Sapien TAVI system when compared with surgical aortic valve replacement.